Isthmus Partners’s Gilead Sciences GILD Stock Holding History

Isthmus Partners’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-180	Closed	-$13K	–	300
2016 Q4	$13K	Buy	180 +75	+71%	+$5.58K	﹤0.01%	245
2016 Q3	$8K	Buy	+105	New	+$8.53K	﹤0.01%	249

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Isthmus Partners's GILD Position: Q1 2017 in Review

Isthmus Partners sold out of Gilead Sciences (GILD) in Q1 2017, closing a stake of 180 shares — an estimated $13K sold.

Isthmus Partners first reported a position in GILD in Q3 2016 and held it in 2 quarters. The position peaked at $13K in Q4 2016. 1,525 funds tracked by Wall St. Rank hold GILD as of Q1 2017.

Isthmus Partners reported no remaining Gilead Sciences position as of Q1 2017 after selling out during the quarter.
Isthmus Partners sold 180 Gilead Sciences shares in Q1 2017, an estimated $13K.
Isthmus Partners first reported a position in Gilead Sciences in Q3 2016 and held it in 2 quarters.
Isthmus Partners's Gilead Sciences position peaked at $13K in Q4 2016.
1,525 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2017.

Based on Isthmus Partners's 13F filing for Q1 2017, filed 10 May 2017.